Develops novel small molecule therapies for neurological disorders, focusing on allosteric modulation of receptors.
Addex Therapeutics Ltd, a biopharmaceutical company in the developmental stage, is dedicated to the discovery, development, and commercialization of small-molecule pharmaceutical products targeting central nervous system (CNS) disorders. Based in Switzerland, Addex Therapeutics specializes in identifying oral small molecule allosteric modulators of G-protein coupled receptors, pioneering therapies that offer new treatment avenues.
The company's leading programs include Dipraglurant, designed for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 targeting epilepsy and other undisclosed CNS disorders, and a GABAB positive allosteric modulator (PAM) for addiction treatment. Through strategic license and collaboration agreements with Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot-Marie-Tooth Association, Addex Therapeutics enhances its research capabilities and accelerates the development of its innovative therapies.
Founded in 2002 and headquartered in Geneva, Switzerland, Addex Therapeutics Ltd (formerly Addex Pharmaceuticals Ltd) continues to advance its mission of transforming CNS disorder treatment through cutting-edge science and strategic partnerships. With a strong pipeline and a commitment to scientific excellence, the company strives to address significant unmet medical needs, bringing hope to patients world wide.